Last reviewed · How we verify
Rivastigmine Transdermal Product — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Rivastigmine Transdermal Product (Rivastigmine Transdermal Product) — UMC Utrecht.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rivastigmine Transdermal Product TARGET | Rivastigmine Transdermal Product | UMC Utrecht | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rivastigmine Transdermal Product CI watch — RSS
- Rivastigmine Transdermal Product CI watch — Atom
- Rivastigmine Transdermal Product CI watch — JSON
- Rivastigmine Transdermal Product alone — RSS
Cite this brief
Drug Landscape (2026). Rivastigmine Transdermal Product — Competitive Intelligence Brief. https://druglandscape.com/ci/rivastigmine-transdermal-product. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab